Effect of metabolic inhibitors on the ability of tumor cells to express antigen and bind complement components C4 and C3.
Metabolic inhibitors commonly used in the treatment of cancer increase the ability of antibody and complement to kill guinea pig tumor cells in vitro. No correlation was found between increased killing and changes in cell surface antigen concentration or binding of complement components C4 and C3.
D000818:Animals; D000937:Antigen-Antibody Reactions / Q000187:drug effects*; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001374:Azacitidine / Q000494:pharmacology; D001666:Binding Sites, Antibody; D006528:Carcinoma, Hepatocellular / Q000276:immunology*; D002462:Cell Membrane / Q000276:immunology; D002478:Cells, Cultured / Q000187:drug effects; D003176:Complement C3; D003181:Complement C4; D003165:Complement System Proteins; D003609:Dactinomycin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D006168:Guinea Pigs; D008113:Liver Neoplasms / Q000276:immunology*; D008727:Methotrexate / Q000494:pharmacology; D009374:Neoplasms, Experimental / Q000276:immunology; D011691:Puromycin / Q000494:pharmacology
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D003176:Complement C3; D003181:Complement C4; D003609:Dactinomycin; D011691:Puromycin; D004317:Doxorubicin; D003165:Complement System Proteins; D001374:Azacitidine; D008727:Methotrexate